Medifast, Inc. manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutrition products in the United States and Asia-Pacific. The company is headquartered in Baltimore, Maryland.
| Revenue (TTM) | $316.93M |
| Gross Profit (TTM) | $219.45M |
| EBITDA | $-5.66M |
| Operating Margin | -5.66% |
| Return on Equity | -12.40% |
| Return on Assets | -4.60% |
| Revenue/Share (TTM) | $28.73 |
| Book Value | $18.99 |
| Price-to-Book | 0.71 |
| Price-to-Sales (TTM) | 0.45 |
| EV/Revenue | 0.0127 |
| EV/EBITDA | 0.05 |
| Quarterly Earnings Growth (YoY) | -87.20% |
| Quarterly Revenue Growth (YoY) | -27.60% |
| Shares Outstanding | $11.18M |
| Float | $8.44M |
| % Insiders | 4.17% |
| % Institutions | 75.88% |
Volatility is currently contracting
MED is shifting toward metabolic health with its 3.0 strategy, targeting broader growth, greater efficiency and a return to profitability.
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Sept.
MED's Trilivy launch marks a major metabolic-health shift, backed by a 10-year roadmap and growing GLP-1 market focus.
Medifast (MED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MED is reshaping its coach network around Executive Directors as productivity rises despite a sharp decline in active earning coaches.
MED's improving coach productivity and client retention point to stabilization, but a shrinking coach base remains a challenge.
Medifast's low valuation and improving coach productivity offer potential, but a shrinking coach base and weak growth keep the turnaround high risk.
Medifast stock gains 13.6% in a month as improving coach productivity and earnings expectations support momentum despite weaker revenue.
Medifast's Trilivy launch and cost cuts could support a Q4 profit turnaround, but shrinking revenue and its coach base keep risks high.
Medifast, Inc. has started to report stabilizing sales through improved coach productivity, shown again in the Q2 report. Stabilized sales provide a pathway to stabilize earnings. MED targets profitability by Q4 already, but the target has to be taken with caution. Due to MED's $15.2 in net cash per share, the stock seems attractive. I estimate 44% upside to $18.8 on the condition that earnings improve near breakeven.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MED and any ticker you trade — then tracks every position and per-strategy win rate.
